A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : EC / endocannabinoid

[Related PubMed/MEDLINE]
Total Number of Papers: 107
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   EC  (>> Co-occurring Abbreviation)
Long Form:   endocannabinoid
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2018 Altered hair endocannabinoid levels in mothers with childhood maltreatment and their newborns. 1-AG, CM, OEA, PEA, SEA
2018 Antimicrobial potential of endocannabinoid and endocannabinoid-like compounds against methicillin-resistant Staphylococcus aureus. AEA, AraS, EC-like, MRSA
2018 Cannabinoid Receptors, Mental Pain and Suicidal Behavior: a Systematic Review. SB
2018 Circulating endocannabinoids and affect regulation in human subjects. 2-AG, AEA
2018 Development of Potent Inhibitors of Fatty Acid Amide Hydrolase Useful for the Treatment of Neuropathic Pain. CBRs, FAAH, MAGL
2018 Endocannabinoid Signaling at Hypothalamic Steroidogenic Factor-1/Proopiomelanocortin Synapses Is Sex- and Diet-Sensitive. DSE, eEPSCs, HFD, POMC, SF, VMN
2018 Endocrine disruptors in the diet of male Sparus aurata: Modulation of the endocannabinoid system at the hepatic and central level by Di-isononyl phthalate and Bisphenol A. AEA, BPA, DINP, ECS, EDC, NPY
2018 Enhancement of Endocannabinoid-dependent Depolarization-induced Suppression of Excitation in Glycinergic Neurons by Prolonged Exposure to High Doses of Salicylate. DCN, DSE
2018 Human Liver Fatty Acid Binding Protein-1 T94A Variant, Nonalcohol Fatty Liver Disease, and Hepatic Endocannabinoid System. 2-MAG, AEA, CB1, FABP1, WT
10  2018 Impact of Fabp1 Gene Ablation on Uptake and Degradation of Endocannabinoids in Mouse Hepatocytes. 2-AG, AEA, ARA
11  2018 Oxidative burst and Dectin-1-triggered phagocytosis affected by norepinephrine and endocannabinoids: implications for fungal clearance under stress. AR, mTOR, NE, PMNs, ROS
12  2018 Reversal of albuminuria by combined AM6545 and perindopril therapy in experimental diabetic nephropathy. DM, DN
13  2018 Role of Nitric Oxide in the Cardiovascular and Renal Systems. EDRF, NO
14  2018 Salivary endocannabinoids and N-acylethanolamines upon mastication of a semisolid food: implications in fat taste, appetite and food liking. MSF, NAE
15  2018 Scp-2/Scp-x ablation in Fabp1 null mice differentially impacts hepatic endocannabinoid level depending on dietary fat. 2-AG, AEA, ARA, HFD, SCP-2
16  2018 Signaling pathways to and from the hypophysial pars tuberalis, an important center for the control of seasonal rhythms. 2-AG, MBH, PT
17  2018 Structural and Functional Interaction of Delta9-Tetrahydrocannabinol with Liver Fatty Acid Binding Protein (FABP1). CD, Delta9-THC, NBD-AEA, WT
18  2018 The Endocannabinoid Reuptake Inhibitor WOBE437 Is Orally Bioavailable and Exerts Indirect Polypharmacological Effects via Different Endocannabinoid Receptors. 2-AG, AEA, FAAH
19  2017 Cannabinoid CB1 /CB2 receptor agonists attenuate hyperactivity and body weight loss in a rat model of activity-based anorexia. ABA, AN
20  2017 Endocannabinod Signal Dysregulation in Autism Spectrum Disorders: A Correlation Link between Inflammatory State and Neuro-Immune Alterations. 2-AG
21  2017 Endocannabinoid concentrations in plasma during the finishing period are associated with feed efficiency and carcass composition of beef cattle. 2-AG, AEA, DOS, RFI
22  2017 Inhibition of Endocannabinoid Degradation Improves Outcomes from Mild Traumatic Brain Injury: A Mechanistic Role for Synaptic Hyperexcitability. 2-AG, mEPSC, mTBI, TBI
23  2017 Inhibitors of oxidative and hydrolytic endocannabinoid degradation do not enhance depolarization-induced suppression of excitation on dorsal cochlear nucleus glycinergic neurons. COX-2, DCN, DSE, PF-CW
24  2017 Insulin induces a shift in lipid and primary carbon metabolites in a model of fasting-induced insulin resistance. aa, FFA, NES, PCM
25  2017 Loss of fatty acid binding protein-1 alters the hepatic endocannabinoid system response to a high-fat diet. AEA, CB1, Fabp1, FTM, HFD, NAFLD
26  2017 Plasma palmitoylethanolamide (PEA) as a potential biomarker for impaired coronary function. CPT, MBF, MOB, OEA, PEA, VCAM-1
27  2017 Regulation of fear extinction by long-term depression: The roles of endocannabinoids and brain derived neurotrophic factor. BDNF, PTSD
28  2017 The cannabinoid system and pain. mPFC
29  2017 The Endocannabinoid System and Autism Spectrum Disorders: Insights from Animal Models. ASD
30  2016 Anandamide mediates cognitive judgement bias in rats. ACI, AEA, CB1, CB2
31  2016 Association between plasma endocannabinoids and appetite in hemodialysis patients: A pilot study. DHEA, LEA, PUFA, SNAQ
32  2016 Cannabinoid receptor signaling regulates liver development and metabolism. CNR, CNR1
33  2016 FABP-1 gene ablation impacts brain endocannabinoid system in male mice. 2-AG, AEA, FABP-1, OEA, WT
34  2016 Female Mice are Resistant to Fabp1 Gene Ablation-Induced Alterations in Brain Endocannabinoid Levels. 2-AG, 2-OG, AEA, ARA
35  2016 Increased Renal 2-Arachidonoylglycerol Level Is Associated with Improved Renal Function in a Mouse Model of Acute Kidney Injury. 2-AG, AKI, BUN, IRI
36  2016 Microencapsulated bitter compounds (from Gentiana lutea) reduce daily energy intakes in humans. CP, EBI, NAE
37  2016 Sex-dependent effects of neonatal maternal deprivation on endocannabinoid levels in the adipose tissue: influence of diet. 2-AG, AEA, HFD, MD, OEA, PEA
38  2015 CB1 cannabinoid receptors mediate endochondral skeletal growth attenuation by Delta9-tetrahydrocannabinol. 2-AG, EGC, WT
39  2015 Diacylglycerol Lipase alpha Knockout Mice Demonstrate Metabolic and Behavioral Phenotypes Similar to Those of Cannabinoid Receptor 1 Knockout Mice. 2-AG, BW, CNR1, KOs, WT
40  2015 Elevated levels of endocannabinoids in chronic hepatitis C may modulate cellular immune response and hepatic stellate cell activation. 2-AG, AEA, CHC, FAAH, HCV, HSC, MAGL, PBMC
41  2015 Endocannabinoid regulation of amyloid-induced neuroinflammation. AD, FAAH
42  2015 Endocannabinoids regulate the activity of astrocytic hemichannels and the microglial response against an injury: In vivo studies. 2-AG, AEA, FAAH, HC, OEA, PEA
43  2015 Oleic acid content of a meal promotes oleoylethanolamide response and reduces subsequent energy intake in humans. HOSO, OEA, SO, VOO
44  2015 The role of the endocannabinoid system in pain. 2-AG, AEA, ECs
45  2014 Alterations in the anandamide metabolism in the development of neuropathic pain. AEA, CCI, DRGs
46  2014 Attenuation of anticipatory nausea in a rat model of contextually elicited conditioned gaping by enhancement of the endocannabinoid system. 2-AG, AEA, AN, FAAH, LiCl, MAGL, VEH
47  2014 Cannabinoid receptor antagonists and fatty acids alter endocannabinoid system gene expression and COX activity. 2-AG, AEA, CB, COX, DAGL, DHA, DHEA, ECS
48  2014 Endocannabinoid modulation of cortical up-states and NREM sleep. CB1, KO
49  2014 Endocannabinoid system and pain: an introduction. AEA, CNS
50  2014 Impact of obesity and bariatric surgery on metabolism and coronary circulatory function. PET
51  2014 The endocannabinoid anandamide regulates the peristaltic reflex by reducing neuro-neuronal and neuro-muscular neurotransmission in ascending myenteric reflex pathways in rats. CB1, e.j.p, GI, IJP
52  2014 The endocannabinoid system: directing eating behavior and macronutrient metabolism. ECS, PUFA
53  2013 Alterations of endocannabinoids in cerebrospinal fluid of dogs with epileptic seizure disorder. 2-AG, AEA, CSF
54  2013 Cannabinoids, Neurogenesis and Antidepressant Drugs: Is there a Link? MAP, PI3K
55  2013 Endocannabinoid system as a potential mechanism for n-3 long-chain polyunsaturated fatty acid mediated cardiovascular protection. LC
56  2013 The role of endocannabinoids system in fatty liver disease and therapeutic potentials. CB1, NAFLD
57  2012 A review of the interactions between alcohol and the endocannabinoid system: implications for alcohol dependence and future directions for research. CB1
58  2012 Cannabinoid receptor type 1 (CB1) activation inhibits small GTPase RhoA activity and regulates motility of prostate carcinoma cells. 2-AG, AEA, CB1
59  2012 Hind limb suspension and long-chain omega-3 PUFA increase mRNA endocannabinoid system levels in skeletal muscle. 2-AG, AA, AEA, EPA, HS, PUFA, WB
60  2012 Inhibiting fatty acid amide hydrolase normalizes endotoxin-induced enhanced gastrointestinal motility in mice. AEA, CB, FAAH, FAEs, GI
61  2012 Inhibition of apolipoprotein A-I gene expression by obesity-associated endocannabinoids. apoA-I, CBR1, HDL-C
62  2012 Interaction of endocannabinoid system and steroid hormones in the control of colon cancer cell growth. AEA, CBs, CRC
63  2012 Lower levels of cannabinoid 1 receptor mRNA in female eating disorder patients: association with wrist cutting as impulsive self-injurious behavior. AN, BDI, BN, CB1, EDs, HCW, SIB
64  2012 Neurotensin inhibits glutamate-mediated synaptic inputs onto ventral tegmental area dopamine neurons through the release of the endocannabinoid 2-AG. DA, NT, VTA
65  2012 NMDA receptors, mGluR5, and endocannabinoids are involved in a cascade leading to hippocampal long-term depression. 2-AG, CB1Rs, CHPG, DHPG, LFS, LTD, mGluR5, NLDE, NMDAR
66  2012 Peripheral endocannabinoid microdialysis: in vitro characterization and proof-of-concept in human subjects. 2-AG, AEA, HPCD, HSA
67  2012 Rimonabant, gastrointestinal motility and obesity. GI
68  2012 Simultaneous UPLC-MS/MS quantification of the endocannabinoids 2-arachidonoyl glycerol (2AG), 1-arachidonoyl glycerol (1AG), and anandamide in human plasma: minimization of matrix-effects, 2AG/1AG isomerization and degradation by toluene solvent extraction. 1AG, 2-AG
69  2011 Central endocannabinoid signaling regulates hepatic glucose production and systemic lipolysis. ACEA, WIN
70  2011 Eicosapentaenoic acid decreases expression of anandamide synthesis enzyme and cannabinoid receptor 2 in osteoblast-like cells. AA, AEA, ALP, CB2, DHA, EPA, FAAH, NAPE-PLD, OA, PUFA
71  2011 Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity. 2-AG, AEA, CPT, MBF
72  2011 Endocannabinoid signaling and energy metabolism: a target for dietary intervention. ---
73  2011 Endocannabinoid system dysfunction in mood and related disorders. CB1, CBD, CNR1, THC
74  2011 New FAAH inhibitors based on 3-carboxamido-5-aryl-isoxazole scaffold that protect against experimental colitis. ---
75  2010 Cannabinoid type 1 receptor blockade induces transdifferentiation towards a brown fat phenotype in white adipocytes. AMPK, CB1R, PGC-1alpha, siRNA, UCP1
76  2010 Endocannabinoid (EC) receptor, CB1, and EC enzymes' expression in primary adipocyte cultures of lean and obese pre-pubertal children in relation to adiponectin and insulin. Ad, EE, IR, PP, Pr
77  2010 Human sperm anatomy: ultrastructural localization of the cannabinoid1 receptor and a potential role of anandamide in sperm survival and acrosome reaction. CB1R, MET-F-AEA
78  2010 The endocannabinoid 2-arachidonoylglycerol (2-AG) and metabolizing enzymes during rat fetoplacental development: a role in uterine remodelling. 2-AG
79  2010 The endocannabinoid signaling system: a marriage of PUFA and musculoskeletal health. PUFA
80  2009 Depolarization-induced release of endocannabinoids by murine dorsal motor nucleus of the vagus nerve neurons differentially regulates inhibitory and excitatory neurotransmission. CB1R, DMNV, DSE, DSI, DVC, eIPSCs
81  2009 Feeding disorders and obesity. CB1
82  2009 Plasma endocannabinoid levels in multiple sclerosis. AEA, FAAH, MS, PEA, PP, RR, SP
83  2009 Responses to the cannabinoid receptor-1 antagonist, AM251, are more robust with age and with high-fat feeding. CB1, HF
84  2009 The endocannabinoid system: a promising target for the management of type 2 diabetes. ---
85  2008 A human fatty acid amide hydrolase (FAAH) functional gene variant is associated with lower blood pressure in young males. BP, ECS, FAAH, YM
86  2008 Acute ethanol suppresses glutamatergic neurotransmission through endocannabinoids in hippocampal neurons. CB1Rs, EPSCs, mEPSC
87  2008 Cat odour-induced anxiety--a study of the involvement of the endocannabinoid system. PAG
88  2008 Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: Effect of high fat diets. 2-AG, AEA, HFDs
89  2008 Overactive endocannabinoid signaling impairs apolipoprotein E-mediated clearance of triglyceride-rich lipoproteins. apo, CB1, IDFP, TG
90  2008 Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors. CD, FAAH, mRNA
91  2008 The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat. AN, CBD, FAAH, VEH
92  2008 The role of adipocyte insulin resistance in the pathogenesis of obesity-related elevations in endocannabinoids. AEA, DIO
93  2007 CB1 knockout mice display impaired functionality of 5-HT1A and 5-HT2A/C receptors. ---
94  2007 Endocannabinoids and cardiovascular prevention: real progress? ---
95  2007 Endocannabinoids and neurodegenerative diseases. AD, AEA, FAAH, HD, ML, MS
96  2007 Quantitative profiling of endocannabinoids and related compounds in rat brain using liquid chromatography-tandem electrospray ionization mass spectrometry. 2-AG, 2-LG, AEA, HEA, OEA, PEA, SPE
97  2007 Role of the endocannabinoid system in regulating cardiovascular and metabolic risk factors. CB1, GI
98  2007 The endocannabinoid system in the regulation of cardiometabolic risk factors. ---
99  2007 The endocannabinoid system: a new target for the regulation of energy balance and metabolism. ---
100  2007 The endocannabinoid system: mechanisms behind metabolic homeostasis and imbalance. CVD